TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Blood

Volumn 121, Issue 16, 2013, Pages 3284-3288

  Dreger, Peter ^a   Schnaiter, Andrea ^b   Zenz, Thorsten ^a,b,c   Böttcher, Sebastian ^d   Rossi, Marianna ^e   Paschka, Peter ^b   Bühler, Andreas ^b   Dietrich, Sascha ^a   Busch, Raymonde ^f   Ritgen, Matthias ^d   Bunjes, Donald ^b   Zeis, Matthias ^g   Stadler, Michael ^h   Uharek, Lutz ⁱ   Scheid, Christof ^j   Hegenbart, Ute ^a   Hallek, Michael ^j   Kneba, Michael ^d   Schmitz, Norbert ^g   Döhner, Hartmut ^b   Stilgenbauer, Stephan ^b   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e UNIVERSITY OF PAVIA   (Italy)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g DEPARTMENT OF CARDIOLOGY   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; NOTCH1 RECEPTOR; PROTEIN P53; PHOSPHOPROTEIN; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; TP53 PROTEIN, HUMAN;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); EVENT FREE SURVIVAL; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NOTCH1 GENE; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; SF3B1 GENE; SURVIVAL RATE; SURVIVAL TIME; TP53 GENE; ALLOTRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; METHODOLOGY; MIDDLE AGED; MUTATION; TREATMENT OUTCOME;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PHOSPHOPROTEINS; RECEPTOR, NOTCH1; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

MLCS; MLOWN;

EID: 84879173666     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-469627     Document Type: Article

References (22)

1. Delgado J, Thomson K, Russell N, et al; British Society of Blood and Marrow Transplantation. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood. 2006;107(4): 1724-1730.
2. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2009;115(13): 2824-2836.
3. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol. 2008; 26(31):5094-5100.
4. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26(30):4912-4920.
5. Farina L, Carniti C, Dodero A, et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica. 2009;94(5):654-662.
6. Dreger P, Döhner H, Ritgen M, et al; German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116(14):2438-2447.
7. Khouri IF, Bassett R, Poindexter N, et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer. 2011;117(20):4679-4688.
8. Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85(6):1580-1589.
9. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473-4479.
10. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011;29(16):2223-2229.
11. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011;118(26):6904-6908.
12. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012; 119(2):521-529.
13. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44(1):47-52.
14. Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012;119(2):329-331.
15. López C, Delgado J, Costa D, et al. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes Cancer. 2012;51(9):881-889.
16. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497-2506.
17. Dreger P, Corradini P, Kimby E, et al; Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1):12-17.
18. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26):1910-1916.
19. Böttcher S, Stilgenbauer S, Busch R, et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia. 2009;23(11):2007-2017.
20. Brown JR, Kim HT, Armand P, et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013;27(2): 362-369.
21. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23(13): 2971-2979.
22. Bosch F, Ferrer A, Villamor N, et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008; 14(1):155-161.